Researchers Find That HBV Reactivation is Unlikely After Biologic Treatment of IBD, Rheumatic Conditions

Researchers Find That HBV Reactivation is Unlikely After Biologic Treatment of IBD, Rheumatic Conditions
In a recent study presented during the European League Against Rheumatism Annual European Congress of Rheumatology (EULAR), a team of researchers found that hepatitis B reactivation after treatment with biologic treatment for rheumatic conditions or IBD was unlikely. The study included a sample of patients with Hepatitis B (HBV), wherein the patients’ serologies were analyzed. Of

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *